JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alonso, O.
Right arrow Articles by Priario, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alonso, O.
Right arrow Articles by Priario, J.
Journal of Nuclear Medicine Vol. 44 No. 10 1561-1565
© 2003 by Society of Nuclear Medicine


Clinical Investigations

Staging of Regional Lymph Nodes in Melanoma Patients by Means of 99mTc-MIBI Scintigraphy

Omar Alonso, MD, PhD1, Miguel Martínez, MD2,3, Lucía Delgado, MD3,4, Ana De León, MD1, Daniela De Boni, MD2,5, Graciela Lago, MD1, Mariela Garcés, MD4, Flávia Fontes, MD1, José Espasandín, MD5 and Julio Priario, MD4

1 Nuclear Medicine Center, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
2 Dermatology Department, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
3 Medicine Department, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
4 Clinical Oncology Department, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
5 National Institute of Oncology, Montevideo, Uruguay

Most first relapses in patients with melanoma occur in regional lymph node basins. Such lesions are frequently diagnosed clinically during the first 2 y of follow-up. In the last few years, our group has been studying the usefulness of 99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy in the evaluation of recurrent melanoma lesions. The aim of the present study was to prospectively evaluate the clinical value of 99mTc-MIBI scintigraphy in the diagnosis of subclinical nodal metastases. Methods: We included 66 patients within 3 mo of melanoma diagnosis, with Breslow thickness > 1.0 mm, all treated with wide local excision of the primary lesion. When 99mTc-MIBI scanning was performed, 49 of them did not have evidence of nodal disease, and 17 had clinically questionable regional lymph node lesions. Planar images of lymph node regions were acquired 10 min after injection, using a dose of 740–1,110 MBq and a large-field-of-view gamma camera equipped with a low-energy high-resolution collimator. Scan findings were confirmed by pathology or by clinical follow-up (median, 35 mo). Results: Thirty of 33 patients with regional lymph node metastases received a correct diagnosis, 14 with palpable lesions and 16 with nonpalpable lesions. In 3 cases that were initially 99mTc-MIBI negative, nodal metastases were found during follow-up. The following diagnostic values were calculated: sensitivity, 0.91 (95% confidence interval [CI], 0.75–0.98); specificity, 0.85 (95% CI, 0.67–0.94); likelihood ratio of a positive test, 6.0 (95% CI, 2.7–13.5); and likelihood ratio of a negative test, 0.11 (95% CI, 0.036–0.32). Conclusion: 99mTc-MIBI scanning may have a secondary role in the staging of regional lymph nodes in patients with clinically localized melanoma who are not good candidates for sentinel node biopsy.

Key Words: 99mTc-MIBI • melanoma • lymph node metastases







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.